• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Which Clot Buster is Best for Acute Coronary Syndromes?

News
Article

Is heparin necessary for a hospitalizedpatient with an acute coronary syndromeif he or she is receiving long-termwarfarin therapy?

Is heparin necessary for a hospitalizedpatient with an acute coronary syndromeif he or she is receiving long-termwarfarin therapy?
----MD
In general, I would recommend stoppingwarfarin and replacing it withheparin plus aspirin. There is noconvincing evidence that warfarin isacutely beneficial in patients withcoronary syndromes.
---- Prediman K. Shah, MD
Director, Division of Cardiology
Cedars-Sinai Medical Center
Los Angeles

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

Sydney Jennings
April 11th 2025
Article

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo / image credit ©Tefi/stock.adobe.com

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo

Grace Halsey
April 1st 2025
Article

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Women's Heart Health News: 5 Studies from ACC.25 / image credit ©Hamza/stock.adobe.com

Women's Heart Health: 5 Studies from ACC.25

Hayden E. Klein
March 28th 2025
Article

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose / image credit: ©New Africa/AdobeStock

Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose

Sydney Jennings
March 27th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.